Henry James International Management Inc. boosted its position in Uniqure NV (NASDAQ:QURE) by 7.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 113,358 shares of the biotechnology company’s stock after purchasing an additional 7,514 shares during the period. Uniqure comprises 1.9% of Henry James International Management Inc.’s portfolio, making the stock its 17th biggest holding. Henry James International Management Inc. owned about 0.30% of Uniqure worth $4,462,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Parametric Portfolio Associates LLC boosted its position in Uniqure by 8.4% in the second quarter. Parametric Portfolio Associates LLC now owns 4,835 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 376 shares during the last quarter. US Bancorp DE boosted its position in Uniqure by 275.5% in the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 427 shares during the last quarter. Griffin Asset Management Inc. purchased a new position in Uniqure in the second quarter worth about $39,000. Royal Bank of Canada boosted its position in Uniqure by 9.7% in the second quarter. Royal Bank of Canada now owns 6,075 shares of the biotechnology company’s stock worth $474,000 after purchasing an additional 536 shares during the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new position in Uniqure in the second quarter worth about $78,000. 69.89% of the stock is currently owned by institutional investors and hedge funds.
In other Uniqure news, insider Robert Gut sold 4,769 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $47.16, for a total value of $224,906.04. Following the completion of the sale, the insider now directly owns 35,378 shares in the company, valued at approximately $1,668,426.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Alexander Edward Kuta III sold 4,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $47.26, for a total value of $189,040.00. Following the completion of the sale, the vice president now owns 30,578 shares of the company’s stock, valued at $1,445,116.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,229 shares of company stock valued at $2,204,241. 2.91% of the stock is owned by company insiders.
Shares of NASDAQ QURE traded up $1.46 during trading hours on Friday, hitting $42.27. 52,002 shares of the company traded hands, compared to its average volume of 802,148. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -18.06 and a beta of 0.84. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average price is $49.15 and its 200 day moving average price is $60.61. Uniqure NV has a 12 month low of $21.98 and a 12 month high of $82.49.
Uniqure (NASDAQ:QURE) last released its earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.08). The company had revenue of $2.47 million for the quarter, compared to the consensus estimate of $1.53 million. Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. Equities analysts anticipate that Uniqure NV will post -3.22 EPS for the current year.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Story: Is the QQQ ETF safe?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.